ALNFL.PA NFL Biosciences SAS

Healthcare Biotechnology Euronext Paris
0.3440 EUR
Close of Nov 7, 2026
0.3415 1.85
Market cap
EUR 4.36M
P/E
-
P/B
21.94x
ROE
-
Dividend yield
-
Fundamental score
0.5/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALNFL.PA undervalued?

Graham number

The Graham number of NFL Biosciences SAS cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

NFL Biosciences SAS fundamental analysis

1 of 11 checks passed

ROE 0/2

Negative ROE (-118.29%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

ROA 0/2

The stock's ROA (-108.13%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

PBV 0/2

The stock's high Price-to-Book Value (P/BV) ratio (10.11x) suggests it's overvalued, potentially making it an expensive investment.

DER 2/2

The stock has a low debt to equity ratio (10%), which means it has a small amount of debt compared to the ownership it holds

Revenue Growth 0/2

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

Net Profit Growth 0/2

The net profit of this company has shown no signs of growth over the last five years, suggesting limited profitability and making it a less attractive investment opportunity.

Assets Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Graham Number 0/1

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

Dividend Growth 0/2

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

Dividend 0/2

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

Buffet Intrinsic Value 0/1

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

NFL Biosciences SAS stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About NFL Biosciences SAS

NFL Biosciences SA, a biotechnology company, engages in the development of botanical drugs in France. The company's pipeline includes NFL-101, a drug candidate for smoking cessation, currently under CESTO II Phase 2 study; NFL-101, a drug candidate for smoking cessation; and NFL-301, a drug candidate for reducing alcohol consumption which is in preclinical stage. It has scientific collaboration with McLean Hospital to deepen the understanding of the mechanism of action of NF…

Full company profile